Naloxone for hepatic encephalopathy
Referencias
Additional references
Als‐Nielsen B, Gluud LL, Gluud C. Dopaminergic agonists for hepatic encephalopathy. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD003047.pub2]
Bernuau J, Durand F, Valla D. Parvovirus B19 infection and fulminant hepatitis. Lancet 1999;353(9154):754‐5.
Boeuf B, Gauvin F, Guerguerian AM, Farrell CA, Lacroix J, Jenicek M. Therapy of shock with naloxone: A meta‐analysis. Critical Care Medicine 1998;26(11):1910‐6.
Conn HO, Leevy CM, Vlahcevic ZR, Rodgers JB, Maddrey WC, Seeff L, et al. Comparison of lactulose and neomycin in the treatment of chronic portal‐systemic encephalopathy. A double blind controlled trial. Gastroenterology 1977;72:573‐83.
Conn HO, Lieberthal MM. Lactulose in the management of chronic portal‐systemic encephalopathy. In: Conn HO, Lieberthal MM editor(s). The hepatic coma syndromes and lactulose. Baltimore: The Williams & Wilkins Company, 1979:323‐39.
Deng JQ. The clinical curative effect observing of naloxone on 50 cirrhotic patients with hepatic encephalopathy. Guo Ji Yi Yao Wei Sheng Dao Bao 2005;11:70‐1.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple graphical test. BMJ (Clinical Research Ed.) 1997;315:629‐34.
Gitlin N. Hepatic encephalopathy. In: Zakim D, Boyer T editor(s). Hepatology. A textbook of liver disease. 3rd Edition. Vol. 1, WB Saunders Company, 1996:605‐17.
Gluud C, Nikolova D, Klingenberg SL, Whitfield K, Alexakis N, Als‐Nielsen B, et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2008, Issue 4. Art. No.: LIVER.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Colloboration, 2008. Available from www.cochrane‐handbook.org.
International Conference on Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice1997 CFR & ICH Guidelines. Vol. 1, PA 19063‐2043, USA: Barnett International/PAREXEL, 1997:1.
Insinna F, Spinnato A. A therapeutic proposal: naloxone for hepatic encephalopathy. Clinical Therapeutics 1987;10(1):32‐5.
Kamel L, Saleh A, Morsy A, Ghali A, El Khayat H. Plasma met‐enkephalin, beta‐endorphin and leu‐enkephalin levels in human hepatic encephalopathy. Eastern Mediterranean Health Journal 2007;13(2):257‐65.
Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine 2001;135:982‐9.
Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analyses?. Lancet 1998;352:609‐13.
Niermeyer S, Van Reempts P, Kattwinkel J, Wiswell T, Burchfield D, Saugstad OD, et al. Resuscitation of newborns. Annals of Emergency Medicine 2001;37:S110‐S125.
O'Malley SS, Cooney JL, Krishnan‐Sarin S, Dubin JA, McKee SA, Cooney NL, et al. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Archives of Internal Medicine 2006;166(6):667‐74.
Poordad FF. Review article: the burden of hepatic encephalopathy. Alimentary Pharmacology and Therapeutics 2007;25(Suppl 1):3‐9.
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
Roozen HG, de Waart R, van den Brink W. Efficacy and tolerability of naltrexone in the treatment of alcohol dependence: oral versus injectable delivery. European Addiction Research 2007;13(4):201‐6.
Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591‐603.
Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408‐12.
Wang SHW, He P, Tian WG, et al. Observation on therapeutic effects of naloxone hydrochloride Injection on 137 patients with hepatic encephalopathy. Chong Qing Medical Journal 2006;35:2070‐1.
Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.) 2008;336:601‐5.
Yurdaydin C, Li Y, Ha JH, Jones EA, Rothman R, Basile AS. Brain and plasma levels of opioid peptides are altered in rats with thioacetamide‐induced fulminant hepatic failure: implications for the treatment of hepatic encephalopathy with opioid antagonists. Journal of Pharmacology and Experimental Therapeutics 1995;273(1):185‐92.
Yurdaydin C, Karavelioglu D, Onaran O, Celik T, Yasa MH, Uzunalimoglu O. Opioid receptor ligands in human hepatic encephalopathy. Journal of Hepatology 1998;29:796‐801.
